Spironolactone in Covid-19 Induced ARDS : The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients

This study intended to evaluate the effects of commonly used diuretic, spironolactone, on oxygenation in covid-19 ARDS patients..

Medienart:

Klinische Studie

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

ClinicalTrials.gov - (2021) vom: 28. Okt. Zur Gesamtaufnahme - year:2021

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Acute Lung Injury
Medical Condition: Respiratory Distress Syndrome, Adult
Recruitment Status: Completed
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Study Type: Observational

Anmerkungen:

Source: Link to the current ClinicalTrials.gov record., First posted: April 15, 2020, Last downloaded: ClinicalTrials.gov processed this data on November 08, 2021, Last updated: November 10, 2021

Study ID:

NCT04345887
10042020

Veröffentlichungen zur Studie:

fisyears:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG003359190